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Abstract
Plasmonically-enhanced DNA-RNA hybrid-based Bioassay for Amplification-free
Quantification of SARS-CoV-2
By
Yuxiong Liu
Master of Science in Biomedical Engineering
Washington University in St. Louis, 2021
Research Advisor: Professor Srikanth Singamaneni

Corona Virus Disease 2019 (COIVD-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), is a highly infectious respiratory illness. Within just a few months,
it spread around the whole world and became a global pandemic. Real-time reverse-transcription
polymerase chain reaction (RT-PCR) works as a gold standard method diagnosing COVID-19 with
high sensitivity and specificity. But due to the programs of RT-PCR, it usually takes more than 24
hours to get the results while specialized devices are also required. False-negative results can
happen as well using RT-PCR which increase the risk of spreading coronavirus. To promote
quicker detection of COVID-19, we would like to demonstrate a novel DNA-RNA hybrid based
fluor-immunoassay for diagnosis of viral RNA. With plasmonic flour (PF) which was previously
developed by our lab, we managed to use the assay to detect the COVID-19 viral RNA accurately
and rapidly. Compared with conventional fluor, PF can exhibit up to thousands-fold brighter signal,
which make it capable of detecting very low concentration of viral RNA. The time cost of the
detection can be reduced to several hours without using advanced devices. Since free of amplifying
steps, we managed to reduce the chance of false positive or false negative. By doing this, both
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quick detection and early-stage confirmation of infection can be enabled which can become a
powerful tool in helping control the spread of COVID-19.

1
Chapter 1: Introduction
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) caused has spread to 220 countries, areas or territories, resulting in a global
pandemic. Individuals suffered COVID-19 usually show a wide range of symptoms from mild
respiratory symptoms similar to influenza to severe respiratory disease with critically ill cases
leading to multiple organ function damage, such as cardiac injury, acute kidney injury, and liver
dysfunction, which can result in a long-term and irreversible decrease in lung function.1-4 As of
now, over 231 million confirmed cases with more than 4.7 million fetal cases worldwide have been
reported.5 Currently, WHO has approved 13 different vaccines and more than 3800 million doses
has been administrated globally.5 However, the number of infected individuals is still rising rapidly
with deploying vaccines. For better control of the spread of COVID-19, accurately and rapidly
diagnosing devices are urgently needed.
Conventionally, a reverse transcription-polymerase-chain-reaction (RT-PCR) is regarded as the
gold standard method for diagnosing RNA virus infection. The RT-PCR works by first amplifying
specifically viral RNA sequences in a patient’s specimen, which makes this test highly sensitive
and specific. But due to prolonged amplification process, RT-PCR need to be processed in a
laboratory environment with expensive and bulky equipment, and time to results need 1-3 days.69

Besides, without proper reference samples, RT-PCR could only produce qualitative results rather

than quantitative viral RNA concentration. Therefore, an ultrasensitive, amplification free, low
cost, easy-to-use and rapid SARS-CoV-2 RNA quantification technique will overcome these
limitations.
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Monoclonal antibody, S9.6, has high affinity and selectivity to DNA-RNA heteroduplexes hybrid
structure without response to single-stranded DNA (ssDNA), double-stranded DNA (dsDNA) or
ribosomal RNA.10-11 The capture of DNA-RNA hybrids by the S9.6 antibody has no sequence
specificity10-11 and the feature has been widely used in R-loop immunoprecipitation experiment 1213

and DNA-RNA double stranded hybrids detection.14-16

In this work, we demonstrate a plasmonically-enhanced DNA-RNA hybrid based fluorimmunoassay for ultrasensitive and quantitative measurement of viral RNA. We introduced viral
RNA complementary DNA-biotin probe as detection sequences. With DNA-RNA heteroduplexes
binding antibody S9.6, viral RNA sequence will be captured and immobilized on the plate. Based
on biotin-streptavidin conjugation, we employed plasmonic-fluor as an ultrabright and highly
specific fluorescent nanolabel instead of conventional fluor. Exhibiting up-to 6700-fold brighter
signal compared to corresponding single fluorophore, plasmonic-fluor is able to decrease the limit
of detection (LOD) up to three magnitude orders. 17 Here, we demonstrate that DNA-RNA hybridbased plasmonically-enhanced immunoassay results in an ultrasensitive and amplification-free
RNA detection method that can accurately quantify SARS-CoV-2 viral RNA concentration in
patients’ samples for clinical diagnosis.
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Chapter 2: Methods & Materials
Plasmonic Fluor
Plasmonic-fluor 650, synthesized according to procedure described previously, was purchased
from Auragent Bioscience, LLC.17
DNA-RNA Hybridization
The oligo nucleic acids used in the project were purchased from IDT. The RNA sequences were
selected from the genome of SARS-CoV-2. (ORF1ab:3901-3955nt; N gene: 28914-28973nt) DNA
probes were designed as complementary sequences of detecting RNA; Complementary DNAbiotin probes were functionalized with a TEG-biotin group on the 3’ end. All these oligo nucleic
acids were purified with HPLC methods and dissolved in Taq buffer. (Supporting Table 1)
Extraction of RNA and RT-qPCR analysis
A total of 52 samples were involved in this project, including 10 delta-SARS-CoV-2 patients
(labeled A-J), 7 alpha/beta SARS-CoV-2 positive saliva samples (labeled K-Q), 8 alpha/beta
SARS-CoV-2 positive nasal swab samples (labeled R-Y), 5 alpha/beta SARS-CoV-2 negative
samples (labeled 1-5), 12 alpha/beta SARS-CoV-2 negative nasal swab samples (labeled 6-17), 5
HCoV-NL63 positive nasal swab samples (labeled a-e), 2 Rhinovirus positive nasal swab samples
(labeled f & g) and 3 Adenovirus positive samples (labeled h-j). (Figure S4) RNA from patients’
saliva and nasal swab samples were extracted by Monarch® Total RNA Miniprep Kit (T2010S,
NEB, England) following the instruction provided by the vendor. The whole extracted saliva or
swab RNA were quantified by Nanodrop (Thermo Scientific, NanoDrop 2000).
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A two-step RT-qPCR was employed to detect N gene and ORF 1ab gene. Reverse transcription
was first performed with PrimeScript RT Master Mix kits (Takara, 036A) following standard
protocol. Subsequently, the amplification was performed using Bio‐Rad CFX384 qPCR
instrument (Bio‐Rad, Hercules, CA) with TB Green® Premix Ex Taq™ (Takara, RR420L).
Primers were listed in Supporting Table 3. The level of ORF1ab and N gene levels were exhibited
with ct value.
Plasmonically enhanced DNA-RNA hybridization immunoassay
All the steps were performed in nuclease-free condition. 50 μl of 20 pg/ml DNA or DNA-biotin
probes and 50 μl of 20 pg/ml target RNA or 50 μl of patients’ RNA solution were added into
nuclease-free 8-strip tube, then being incubated at 56℃ for 20 mins. Hybridized DNA/RNA (final
concentration: 10 pg/ml) working as standards was serial diluted before introducing to prefunctionalized plate.
The black wall microtiter plates (Greiner bio-one, E20043K9) were functionalized with S9.6
DNA-RNA hybrid antibody (1 μg/ml in PBS, Active Motif, 65683) through overnight incubation
at room temperature followed by blocking with 1X PBS containing 1% BSA. After three times
washing with PBST (1X PBS, 0.05% Tween-20), 100 μl of hybridized solution was added into
wells and the plate was incubated for 1 hour at room temperature.
With DNA + biotin conjugated detection antibody and DNA-biotin + biotin conjugated detection
antibody forms, the plate was subsequently washed with PBST three times and incubated with
biotin-conjugated DNA-RNA hybrid antibody (0.5 μg/ml in 1XPBS 1%BSA, Active Motif,
65683) for 1 hour. Then the plate was exposed to plasmonic-fluor (extinction 1.0) for 15 mins.
The detailed assay protocol was shown in Supporting Table 3.
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With DNA-biotin detection form, the plate was directly incubated with plasmonic-fluor (extinction
1.0) for 15 minutes after 3 times washing. The plate was imaged using fluorescence imager with
the following scanning parameters: 650nm wavelength, exposing 5000ms. The detailed assay
protocol was shown in Supporting Table 4.
Digital-resolution detection DNA-RNA hybridization immunoassay
All hybridized steps were the same with plasmonic-enhanced DNA/RNA hybridization
immunoassay. After hybridization, the standards and patients’ samples were incubated within S9.6
DNA-RNA hybrid antibody (1 μg/ml in PBS, Active Motif, 65683) pre-coated glass bottom plates
(Cellvis, P96-1.5H-N). The plate was subsequently exposed to plasmonic-fluor (extinction 1.0) for
15 mins after 3 times PBST washing.
Statistical Analysis
The statistical analysis was performed with GraphPad Prism 6 and all values were expressed as
mean ± s.d. For testing the statistical difference between two groups, an unpaired two-tailed ttest was used. bioassays. For evaluating the correlation strength, Pearson r analysis was used.
Statistical significance of the data was calculated at 95% (P < 0.05) confidence intervals. We
employed four-parameter logistic or polynomial fit to calculate the standard curves of the assay.
LOD is defined as the analyte concentration corresponding to the mean fluorescence intensity of
blank plus three times of its standard deviation (mean + 3σ). Technical replicates with n=2.
Origin 2016 was employed for calculating the LOD.
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Chapter 3: Results & Discussion
Ultrabrightness of Plasmonic Flour (PF)
To evaluate the feasibility of plasmonic fluor as an ultrabright fluorescence label, we set out to
determine and compare the brightness of plasmonic-fluor with conventional fluorophores.
Plasmonic-fluor-Cy5 (PF) used in this work is comprised of Au@Ag nanorods as a plasmonic
nanoantenna and is coupled with bovine serum albumin and streptavidin-Cy5. (Figure 2A & B)
The BSA-biotin coated microtiter plate was exposed to PF and streptavidin-Cy5, respectively. The
fluorescence intensity corresponding to plasmonic-fluor was found to be nearly 1100-fold higher
compared to that of streptavidin-Cy5. (Figure 2C).
Detection forms of DNA-RNA hybrid-based immunoassay
To investigate the applicability of plasmonic-fluor as a reporter in DNA-RNA hybrid-based
immunoassay, we introduced two different PF binding sites in the detection forms: S9.6 antibody
conjugated with biotin and DNA probes labeled with biotin. These two binding sites lead to two
detection forms: Capture S9.6-RNA-DNA-Detection-Biotin-PF (RNA-DNA-Det-bio-PFLISA)
and Capture S9.6-RNA-DNA-biotin-PF (RNA-DNA-biotin-PFLISA). (Figure 1) Furthermore, to
achieve higher binding efficiency, we also combine these two binding sites forming a Capture
S9.6-RNA-DNA-biotin-Detection-biotin-PF (RNA-DNA-bio-Det-bio-PFLISA) form.
To accurately capture SARS-CoV-2 viral RNA, two target gene sequences (N gene and ORF1ab)
were selected from the SARS-CoV-2 genome and designed target RNA complementary DNA
probes. (Figure 1, Supporting Table 1) Under the hybridized thermal cycle, DNA probes will
accurately bind with specific target RNA forming a DNA-RNA helix hybridization structure
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followed by being immobilized on an S9.6 antibody pre-coated plate. To form more detectable
hybridized helix structure, averagely mixed N and ORF1ab DNA probes were set as another
detecting group. With N and ORF1ab DNA probes, N gene RNA and ORF1ab RNA will form
heteroduplexes hybridized structure to get the highest signal.

Figure 1: Schematic of hybridization-based RNA-DNA-Det-bio-PFLISA and RNA-DNA-biotinPFLISA.

To evaluate the specificity of plasmonically enhanced DNA-RNA hybrids based immunoassay,
single strand RNA (10 fg/ml), single strand DNA (10 fg/ml), single strand DNA-biotin (10 fg/ml),
random RNA solution extracted from 3T3 cell line (10 fg/ml), random RNA solution extracted
from 3T3 cell line incubated with DNA-biotin (10f g/ml) and random RNA solution extracted
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from 3T3 cell line incubated with DNA probe (10 fg/ml) were set as control group. All these nuclei
acids solution was added into S9.6 pre-coated plate and then incubated with biotin conjugated S9.6
detection antibody followed by exposing to PF. Ideally, without DNA-RNA hybridization
structure, these control groups showed no statistic differences of fluorescence intensity with blank
group (Taq buffer). (Figure 2D & E) Meanwhile, ORF1ab RNA and DNA/DNA-biotin probes
were chosen as demonstration samples followed by incubating at hybridized thermal cycle: 56 ℃
for 20 min then 4℃ for 5 min. The success of hybridization was validated by RNA electrophoresis
and paper-based dot assay. (Figure S1) The hybridized RNA-DNA/DNA-biotin solution was
added to the S9.6 antibody pre-coated plate. Within DNA-Det-bio-PFLISA and DNA-bio-Detbio-PFLISA, the plate was then incubated with biotin conjugated S9.6 antibody for 1h followed
by exposing with plasmonic-fluor for 20 mins. Within DNA-bio-PFLISA form, the plate was
directly exposed to plasmonic-fluor for 20 mins. To achieve optimal detection form, we first
compare the fluorescence intensity among hybridized RNA-DNA-Detection-biotin PFLISA (10
fg/ml), hybridized RNA-DNA-biotin PFLISA (10 fg/ml) and hybridized RNA-DNA-biotinDetection-biotin PFLISA (10 fg/ml). It’s noted that these three detection forms having similar
fluorescence intensity. (Figure 2D & E)
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Figure 2. Plasmoncally enhanced DNA-RNA hybridized assay. A) Vis–NIR extinction spectra of
plasmonic-fluor, showing longitudinal plasmonic extinction band at 650nm; B) TEM image
plasmonic-fluor–Cy5; C) Fluorescence intensity histogram corresponding to conventional fluor
and plasmonic-fluor showing nearly 100-fold brighter fluorescence intensity of plasmonic-fluor
compared to conventional fluor. Error bars, s.d. (n = 2 independent tests). Data statistically
significant ** P < 0.01 by two-tailed unpaired t-test. D) Fluorescence intensity map and histogram
E) corresponding to Hybridized RNA-DNA, Hybridized RNA-DNA-biotin, Hybridized RNADNA-biotin-Det-biotin, Single Strand RNA, Single Strand DNA-biotin, Single strand DNA,
Random RNA solution extracted from 3T3 cell line, Random RNA solution extracted from 3T3
cell line incubated with DNA-biotin (10f g/ml), Random RNA solution extracted from 3T3 cell
line incubated with DNA probe (10 fg/ml) and Blank (Reaction Buffer). Error bars, s.d. (N =2).
Data statistically significant. ****P < 0.0001, *** P< 0.001 by Student t test.
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Sensitivity of different detection forms
Then to accurately quantify the concentration of viral RNA, serial diluted target commercial RNA
was added with equal concentration of designed DNA or DNA-biotin probes and then incubated
at hybridized thermal cycle temperature, leading to serial concentration of hybridized RNA-DNA
or RNA-DNA-biotin. We employed this serial concentration of hybridized nucleic acids as
standards. After the downstream PFLISA process, an increase in the concentration of the RNADNA or RNA-DNA-biotin resulted in a dose dependent increase in fluorescence in tensity forming
standard curves. (Figure 3) Subsequently, the sensitivity was compared, shown as limit of
detection (LOD, defined as mean+3σ of blank), of the three detection forms. Conventional RNADNA-biotin-enzyme-linked immunosorbent assay (RNA-DNA-bio-ELISA) worked as control
group with the LOD at 0.69 fM (ORF1ab), 12.85 fM (N gene), and 6.8 fM (mixture of N and
ORF1ab). (Figure 3A-D) The average LOD of DNA-bio-PFLISA (Figure 3E-H, Figure S2), DNADet-bio-PFLISA (Figure 3I-L, Figure S2), and DNA-bio-Det-bio PFLISA (Figure 3M-P, Figure
S2) was 24.635 aM, 21.55 aM, and 14.36 aM, respectively. Compared with ELISA, the LOD of
three PFLISA detection forms showed nearly 230-1000-fold improvement, while there exist no
statistical differences between the three PFLISA detection form (Figure S2). Then the detection
duration was compared among DNA-bio-PFLISA (1h 40mins, Supporting Table 3), DNA-Detbio-PFLISA (2h 40 mins Supporting Table 4), and DNA-bio-Det-bio-PFLISA (2h 40min,
Supporting Table 4). With shortest detection duration (1h 40min) and similar LOD, DNA-bioPFLISA was selected as final detection form.
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Figure 3. LOD comparison of RNA-DNA-biotin-ELISA, RNA-DNA-biotin-PFLISA, RNADNA-Detection antibody-biotin-PFLISA, RNA-DNA-biotin-Detection antibody-biotin-PFLISA.
A) Schematic of RNA-DNA-biotin-ELISA assay; B-D) Plots showing different target RNA (ORF
1ab, N gene and ORF1ab & N gene) dose dependent standard curve of RNA-DNA-biotin-ELISA
assay. Technical replicates with n=2, and data is presented as mean + sd. The LOD was found to
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be 5.1 fM, 12.85 fM and 6.8 fM. E) Schematic of RNA-DNA-biotin-PFLISA; F-H) Plots showing
different target RNA (ORF 1ab, N gene and ORF1ab & N gene) dose dependent standard curve of
RNA-DNA-biotin-PFLISA assay. Technical replicates with n=2, and data is presented as mean +
sd. The LOD was found to be 27.8 aM, 37.4 aM and 28 aM, which is nearly 270 times lower than
LOD of RNA-DNA-biotin-PFLISA. I) Schematic of RNA-DNA-Detection antibody-biotinPFLISA; J)-L) Plots showing different target RNA (ORF 1ab, N gene and ORF1ab & N gene)
dose dependent standard curve of RNA-DNA-Detection antibody-biotin-PFLISA. Technical
replicates with n=2, and data is presented as mean + sd. The LOD was found to be 48.65 aM, 7
aM and 14 aM. M) Schematic of RNA-DNA-biotin-Detection antibody-biotin-PFLISA; N-P)
Plots showing different target RNA (ORF 1ab, N gene and ORF1ab & N gene) dose dependent
standard curve of RNA-DNA-biotin-Detection antibody-biotin-PFLISA. Technical replicates with
n=2, and data is presented as mean + sd. The LOD was found to be 13.9 aM, 5.34 aM and 0.8 aM.

Digital assay optimizing LOD of PFLISA
To further optimize plasmonically enhanced DNA-RNA hybrid-based immunoassay, we
introduced a more sensitive digital particle counting system within DNA-bio-Plasmonic-fluor
form, which could accurately count the number of binding particles in different hybrid DNA-RNA
concentration groups. (Figure 4D Figure S3) DNA-biotin-plasmonic-fluor assay was performed
on a standard glass bottom plate followed by analyzing fluorescence intensity with LICOR system
and counting particle numbers with microscope. (Figure 4 A-D) The LODs of digital assay were
0.02 aM (ORF1ab), 0.8 aM, (N gene) and 0.3 aM (mixture of N and ORF1ab), while the LODs of
PFLISA were 16 aM (ORF1ab), 91 aM (N gene) and 12.29 aM (mixture of N and ORF1ab).

13
(Figure 4A-C) The average LOD of digital assay shows nearly 300-fold lower compared with
PFLISA.

Figure 4 Comparison of detection sensitivity between digital detection form and plasmonic
enhanced form. Plots showing SARS-CoV-2 RNA ORF1ab A), N gene B) and a mixture of
ORF1ab & N C) does-dependent response and LOD in digital assay (red) and plasmonic enhanced
assay (black). Technical replicates with n=2, and data is presented as mean + s.d. A)-C) Digital
assay has 40-810 times lower limited of detection compared with PFLISA assay. D) Plot showing
particles number changing dependent on ORF1ab RNA concentration. E) Expanded regions from
D) (Dashed part). Each red dot represents a single plasmonic-fluor.
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PFLISA performance on COVID patient samples
The usage of our method was also explored in testing patients’ samples. To determine the
feasibility of using DNA-biotin-PFLISA assay in various biopsy specimen, two commonly used
sample forms, nasal swab samples and saliva samples, were used. (Figure 5 A-C, Figure S4) RNA
was extracted from transportation liquid of nasal swab samples and saliva samples followed by
measuring whole RNA concentration. 25ul sample RNA solution was mixed with 12.5ul 20 fg/ml
N gene DNA probe and 12.5ul 20 fg/ml ORF1ab DNA probe. This mixture solution was incubated
at hybridized thermal cycle for 20min and then added into S9.6 antibody pre-coated plate.
Subsequently, the plate was exposed with plasmonic-fluor (ext=1.0), and the fluorescence intensity
was collected with LICOR plate reader. Based on standard curve, the viral RNA concentration of
patients’ samples was listed in Figure 5B. Meanwhile, qRT-PCR was employed as gold standard
to validate measurement accuracy.
Then concentration of viral RNA within the same tissue biopsy tested by qRT-PCR revealed a
good qualitative correlation with those evaluated by DNA-biotin-PFLISA assay (r2=0.37) (Figure
5C). These results indicate the high accuracy of this novel assay in measuring the concentration of
viral RNA in complex biospecimen.
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Figure 5 DNA-biotin-PFLISA assay and qRT-PCR of patient’s samples. A) The ORF1ab level of
delta-SARS-CoV-2 patients’ samples, alpha/beta-SARS-CoV-2 patients’ samples, SARS-CoV-2
negative individuals and other virus (Corona-NL63 positive, Rhinovirus positive and Adenovirus
positive) infected patients’ samples. Results are shown by Ct value. The COVID positive threshold
was set at 39. The Ct value of un-detectable samples were set at 45. B) The concentration of
ORF1ab gene quantified by DNA-biotin-PFLISA assay ofdelta-SARS-CoV-2 patients’ samples,
alpha/beta-SARS-CoV-2 patients’ samples, SARS-CoV-2 negative individuals and other virus
(Corona-NL63 positive, Rhinovirus positive and Adenovirus positive) infected patients’ samples.
The positive threshold was set at LOD (13aM) of standard curve. C) The correlation between
ORF1ab gene (r2 = 0.37) tested by DNA-biotin-PFLISA assay and qRT-PCR. Tested by Pearson
r.
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Detection of Delta variant patient samples
As a single strand RNA virus, the emerging variants of SARS-CoV-2 makes the control of
pandemic more difficult. Currently, the B.1.617.2 (Delta) variant of SARS-CoV-2, which was first
detected in India, has overtaken the alpha variant (B.1.1.7) to make it the most dominant strain
circulating in approximately 60 countries. 18-20 Compared with alpha variant, delta variant is able
to cause more severe symptoms and leads to higher hospital admission rate. 21 To investigate
whether our DNA-biotin-PFLISA assay is able to detect different SARS-CoV-2 variants, earlier
variant was employed, which include alpha/beta SARS-CoV-2, positive patients (n=15) and delta
variant SARS-CoV-2 positive patients (n=10) as our positive samples. (Figure 5A&B, Figure S4)
In our case, we specially selected delta-positive patients with ct value lower than 20, indicating
higher virus load. In comparison, alpha/beta SARS-CoV-2 positive patients with a ct value higher
than 25 was also employed. (Figure 5A) The SARS-CoV-2 negative individuals were selected as
the negative control. Results showed that DNA-biotin-PFLISA could distinguish higher virusinfected patients, lower virus-infected patients, and non-virus infecting individuals. (Figure 5B)
The LOD of the standard curve (13 aM, dash line in Figure 5B) was set as a diagnostic threshold.
Furthermore, to verify the specificity of DNA-biotin-PFLISA assay, three other viruses showing
similar symptoms to COVID-19 were also selected, which are human coronavirus NL63 (HCoVNL63 n=5), Adenovirus (n=2) and Rhinovirus (n=2). (Figure 5B) As an α-CoV classification
virus, HCoV-NL63 has genome similar with SARS-CoV-2 (β-CoV) associating with common
upper respiratory tract infections in immunocompetent individuals.22-23 SARS-CoV-2 negative
individuals were selected as negative control. Results showed that there exist no statistic
differences between control group (other virus infected group) and negative group, indicating
DNA-biotin-PFLISA assay is able to distinguish different viruses’ infectious patients.
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Chapter 4: Conclusion
To establish a novel method which can detect COVID-19 viral RNA quickly and accurately, we
demonstrated a plasmonically-enhanced DNA-RNA hybrid based fluor-immunoassay. The target
genes we chose are N gene and ORF1ab gene of viral genome which are commonly used in
COVID-19 detection.
With the usage of PF, we managed to increase the fluorescence intensity by nearly 1100-fold which
showed that this can be ultrasensitive when applied to detect very low concentration of viral RNA.
For the immunoassay, we had three forms of PFLISA design which turned out that there are no
significant differences in LOD. Compared with conventional ELISA, all three PFLISA detections
showed nearly 230-1000-fold improvement. And considering the similar LODs of the three forms,
we decided to choose the shortest time-cost form. We also introduced a digital particle counting
system which can accurately count the number of binding particles. This system helped us improve
further with the LOD reaching 300-fold lower compared with PFLISA.
Then we tried our method in testing patients’ samples. Viral RNA was extracted from samples
which have different amount of viral RNA. By running the assay, we found out that the
concentration of viral RNA was qualitative correlated with the ct value of the samples, which
proves that our method can detect the viral RNA even under an extremely low concentration.
Considering the emerging variants of COVID-19 across the world, we tried delta-positive patient
samples with our method. Since the sequences we chose are highly conservative, we are still able
to detect the delta variant samples.
We think that our newly developed method can be used in future COVID detection. Since PFLISA
doesn’t need bulky equipment, it’s promising that this method can be widely used especially in
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non-well-developed areas. And we hope this method can contribute to the control of this pandemic
and help stop the spread of COVID-19.
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Future Plan
As mentioned above, we have demonstrated that our method can distinguish COVID patients’
samples from normal persons’ samples and other virus infected patients’ samples. It can work
within 2 hours while maintaining high accuracy. Although we tried our method to successfully
detect delta variant of COVID, we didn’t complete the distinguishment of different variants of
COVID.
To solve this problem, we are planning to add more key sequences of different variants. For
example, the spike protein mutation sites of delta variant have been identified. (L452R, tbl478K,
D614G, tbl19R, Δ157-158, P681R, and D950N)24 We can use these mutations to design different
DNA probe to bind with mutated viral RNA to show how well this method can tell the difference.
We believe with the change on DNA probe design, this method will be able to distinguish different
variants of COVID.
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Appendix: Supporting Materials
Supporting Figure 1

Figure S1. Characterization of Hybridization. A) RNA electrophoresis of 250 ng DNA/RNA, 500
ng DNA/RNA, 500 ng DNA and 500 ng RNA; B) Schematic of dot assay; C) Hybridized
DNA/RNA dose dependent dot assay.

Supporting Figure 2

Figure S2. LOD Comparison of RNA-DNA-biotin-PFLISA, RNA-DNA-Detection antibodybiotin-PFLISA, RNA-DNA-biotin-Detection antibody-biotin-PFLISA and RNA-DNA-biotin
based digital assay. Left: LOD of RNA-DNA-biotin-PFLISA, RNA-DNA-Detection antibody-
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biotin-PFLISA, RNA-DNA-biotin-Detection antibody-biotin-PFLISA and RNA-DNA-biotin
based digital assay. There are no statistic differences between RNA-DNA-biotin-PFLISA, RNADNA-Detection antibody-biotin-PFLISA and RNA-DNA-biotin-Detection antibody-biotinPFLISA. (One-Way ANOVA, p= 0.86, n=3). LOD of RNA-DNA-biotin-PFLISA and RNA-DNAbiotin based digital assay shown statistic difference. (Unpaired t test, n=3, *p<0.05)

Supporting Figure 3

Figure S3. Plasmonic-fluor particles number changing dependent on concentration of N gene,
ORF1ab and mixture genes (N gene and ORF1ab) RNA.
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Supporting Figure 4.

Figure S4 Plots showing SARS-CoV-2 gene of patients’ samples tested by RT-PCR (Left Y axis,
shown as Ct value-1) and DNA-biotin-PFLISA (Right Y axis). Patients’ samples were divided into
Delta-SARS-CoV-2 nasal swab samples (labeled A-J), alpha/beta SARS-CoV-2 positive saliva
samples (labeled K-Q), alpha/beta SARS-CoV-2 positive nasal swab samples (labeled R-Y),
alpha/beta SARS-CoV-2 negative saliva samples (labeled 1-5), alpha/beta SARS-CoV-2 negative
nasal swab samples (labeled 6-17), HCoV-NL63 positive nasal swab samples (labeled a-e),
Rhinovirus positive nasal swab samples (labeled f & g) and 3 Adenovirus positive samples (labeled
h-j).
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Supporting Table 1. Sequences of DNA and RNA used in hybridization.
Gene Name

RNA sequence
(5’-3’)

DNA probe
(5’-3’)

N (2891428973)

CTT GAC AGA TTG
AAC CAG CTT GAG
AGC AAA ATG TCT
GGT AAA GGC

GCC TTT ACC AGA
CAT TTT GCT CTC
AAG CTG GTT CAA
TCT GTC AAG

ORF 1ab
(3901-3955)

GCC AUU UAU AAC
UGA AAG UAA ACC
UUC AGU UGA ACA
GAG AAA ACA AGA
UGA UAA G

CTT ATC ATC TTG
TTT TCT CTG TTC
AAC TGA AGG TTT
ACT TTC AGT TAT
AAA TG GC

Biotin conjugated DNA
probe
(5’-3’)
GCC TTT ACC AGA
CAT TTT GCT CTC
AAG CTG GTT CAA
TCT GTC AAG
/3BioTEG/
CTT ATC ATC TTG
TTT TCT CTG TTC
AAC TGA AGG TTT
ACT TTC AGT TAT
AAA TG GC
/3BioTEG/
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Gene
Name
ORF
1ab
N gene

Supporting Table 2. Sequences of primers used for qRT-PCR
Forward
Reverse
CCC TGT GGG TTT TAC ACT
TAA
GGG GAA CTT CTC CTG CTA
GAA T

ACG ATT GTG CAT CAG CTG A
CAG ACA TTT TGC TCT CAA GCT G
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1

2
3

Supporting Table 3: DNA-biotin detection form:
Reagent
Concentration and volume (per well)
S9.6 DNA-RNA
1 μg/ml in 100 μl PBS
hybrid antibody
Three times wash with PBST
BSA
1% in 300 μl PBS
Three times wash with PBST
Hybridized 20 mins at 56 ℃, 5 min at 4℃

Incubation time
Overnight

1 hour

Three times wash with PBST
4

Product solution

5

Plasmonic Flour

100 μl
Three times wash with PBST
Extinction 1.0
Three times wash with PBST

1 hour
15 minutes
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Supporting Table 4: DNA + biotin conjugated detection antibody and DNA-biotin + biotin
conjugated detection antibody detection form:
Reagent
Concentration and volume (per well)
Incubation time
1
S9.6 DNA-RNA
1 μg/ml in 100 μl PBS
Overnight
hybrid antibody
Three times wash with PBST
2
BSA
1% in 300 μl PBS
1 hour
Three times wash with PBST
3
Hybridized 20 mins at 56 ℃, 5 min at 4℃
Three times wash with PBST
4
5

6

100 μl
Three times wash with PBST
Biotin conjugated S9.6
0.5 μg/ml in 100 μl PBS
DNA-RNA hybrid
antibody
Three times wash with PBST
Plasmonic Flour
Extinction 1.0
Three times wash with PBST
Product solution

1 hour
1 hour

15 minutes

